Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea

(2019) Julio Rosenstock et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2019 EXECUTIVE SUMMARY

(2019) Alan J. Garber et al.   Endocrine Practice

Incorporating and Interpreting Regulatory Guidance on Estimands in Diabetes Clinical Trials: The PIONEER 1 Randomized Clinical Trial as an Example

(2019) Vanita R. Aroda et al.   DIABETES OBESITY & METABOLISM

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

(2019) Richard Pratley et al.   LANCET

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

(2019) Hertzel C Gerstein et al.   LANCET

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

(2019) Thomas R Pieber et al.   Lancet Diabetes & Endocrinology

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

(2018) Bernhard Ludvik et al.   Lancet Diabetes & Endocrinology

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs

(2018) Michal Witkowski et al.   Diabetes Therapy

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs

(2018) Michal Witkowski et al.   Diabetes Therapy

Efficacy and Safety of Once-weekly Dulaglutide Versus Insulin Glargine in Mainly Asian Patients with Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea: a 52-week Open-label, Randomized Phase 3 Trial

(2018) Weiqing Wang et al.   DIABETES OBESITY & METABOLISM

6. Glycemic Targets: Standards of Medical Care in Diabetes—2019

(2018)   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2018) Melanie J. Davies et al.   DIABETES CARE

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

(2017) Bo Ahrén et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

(2017) Vanita R Aroda et al.   Lancet Diabetes & Endocrinology

Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014

(2017) Ginger Carls et al.   Diabetes Therapy

Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014

(2017) Ginger Carls et al.   Diabetes Therapy

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

(2017) Mirko Sikirica et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials

(2017) Michelle Orme et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Role of glucagon-like peptide 1 receptor agonists in management of obesity

(2016) D. Isaacs et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update

(2016)   Canadian Journal of Diabetes

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

(2016) Julio Rosenstock et al.   DIABETES CARE

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

(2016) Michael Nauck et al.   DIABETES CARE

Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial

(2016) L. Zang et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial

(2016) T. S. Bailey et al.   DIABETES OBESITY & METABOLISM

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

(2016) Juan P Frías et al.   Lancet Diabetes & Endocrinology

A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus

(2016) Sheena Kayaniyil et al.   Diabetes Therapy

A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus

(2016) Sheena Kayaniyil et al.   Diabetes Therapy

Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments

(2015) Francesco Zaccardi et al.   ANNALS OF INTERNAL MEDICINE

Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study

(2015) E. Araki et al.   DIABETES OBESITY & METABOLISM

Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

(2015) Feng Sun et al.   Diabetes Technology & Therapeutics

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015 —EXECUTIVE SUMMARY

(2015) Yehuda Handelsman et al.   Endocrine Practice

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

(2014) Bo Ahrén et al.   DIABETES CARE

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled

(2014) J. Reusch et al.   DIABETES OBESITY & METABOLISM

Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia)

(2014) Chang Yu Pan et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

(2014) Peter N. Weissman et al.   DIABETOLOGIA

Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)

(2014) Julio Rosenstock et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

(2014) Kathleen M Dungan et al.   LANCET

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial

(2014) Michaela Diamant et al.   Lancet Diabetes & Endocrinology

Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus

(2014) Daniel Lorber   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: A cohort study of 8486 primary-care patients

(2013) J. Bodegard et al.   DIABETES & METABOLISM

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)

(2013) J. Rosenstock et al.   DIABETES CARE

Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)

(2013) Bo Ahrén et al.   DIABETES CARE

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)

(2013) M. Pinget et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)

(2013) G. B. Bolli et al.   DIABETIC MEDICINE

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial

(2013) B. Charbonnel et al.   DIABETOLOGIA

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

(2013)   EUROPEAN HEART JOURNAL

Mechanisms of Diabetic Complications

(2013) Josephine M. Forbes et al.   PHYSIOLOGICAL REVIEWS

Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study

(2012) Pedro de Pablos-Velasco et al.   CLINICAL ENDOCRINOLOGY

Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes

(2012) G. Derosa et al.   DIABETIC MEDICINE

Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs

(2012) N. Hex et al.   DIABETIC MEDICINE

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

(2012) Baptist Gallwitz et al.   LANCET

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

(2012) John B Buse et al.   LANCET

Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus

(2012) Linong Ji et al.   Journal of Diabetes Investigation

Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia

(2011) B. Gallwitz et al.   DIABETES CARE

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability

(2011) A. J. Garber   DIABETES CARE

Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients

(2011) Giuseppe Derosa et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2

(2011) David C. Hoaglin et al.   VALUE IN HEALTH

Exploring reasons for very poor glycaemic control in patients with Type 2 diabetes

(2011) Hamida Khan et al.   Primary Care Diabetes

A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin

(2010) J. Liutkus et al.   DIABETES OBESITY & METABOLISM

Exenatide Versus Glibenclamide in Patients with Diabetes

(2010) G. Derosa et al.   Diabetes Technology & Therapeutics

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

(2010) Georgia Salanti et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

(2010) Richard M Bergenstal et al.   LANCET

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Bias modelling in evidence synthesis

(2008) Rebecca M. Turner et al.   JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY